CSat Investment Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

CSat Investment Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$25K	Sell	163 -19	-10%	-$2.94K	0.02%	342
2020 Q4	$28K	Sell	182 -4,318	-96%	-$555K	0.03%	281
2020 Q3	$515K	Sell	4,500 -531	-11%	-$57.3K	0.05%	178
2020 Q2	$565K	Buy	5,031 +2,962	+143%	+$314K	0.07%	164
2020 Q1	$185K	Buy	2,069 +220	+12%	+$21.6K	0.04%	251
2019 Q4	$200K	Buy	1,849 +972	+111%	+$104K	0.05%	233
2019 Q3	$86K	Buy	877 +130	+17%	+$14.7K	0.03%	349
2019 Q2	$98K	Buy	747 +668	+846%	+$86.1K	0.03%	300
2019 Q1	$11K	Sell	79 -16	-17%	-$1.99K	0.01%	426
2018 Q4	$9K	Buy	95 +28	+42%	+$3.31K	0.01%	431
2018 Q3	$9K	Buy	67 +11	+20%	+$1.38K	0.01%	395
2018 Q2	$7K	Buy	+56	New	+$6.54K	﹤0.01%	425

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSat Investment Advisory's ALXN Position: Q1 2021 in Review

CSat Investment Advisory reduced its Alexion Pharmaceuticals (ALXN) stake by 10% in Q1 2021, selling an estimated $2.94K and leaving 163 shares worth $25K. The position accounts for 0.02% of the portfolio, ranked #342.

CSat Investment Advisory first reported a position in ALXN in Q2 2018 and has held it in 12 quarters since. The position peaked at $565K in Q2 2020. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

CSat Investment Advisory held 163 shares of Alexion Pharmaceuticals worth $25K as of Q1 2021.
CSat Investment Advisory sold 19 Alexion Pharmaceuticals shares in Q1 2021, an estimated $2.94K.
Alexion Pharmaceuticals made up 0.02% of CSat Investment Advisory's portfolio in Q1 2021, its #342 holding.
CSat Investment Advisory first reported a position in Alexion Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
CSat Investment Advisory's Alexion Pharmaceuticals position peaked at $565K in Q2 2020.
753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on CSat Investment Advisory's 13F filing for Q1 2021, filed 13 May 2021.